Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Summit Therapeutics Inc SMMT

Healthcare Biotechnology
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF... see more

Recent & Breaking News (NDAQ:SMMT)

Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases With Data Showing Summit’s Ridinilazole Achieved Statistical Superiority over Vancomycin in the Treatment of C. Difficile Infection

GlobeNewswire April 28, 2017

Summit Therapeutics to Present at the Needham Healthcare Conference

GlobeNewswire March 30, 2017

Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017 and Operational Progress

GlobeNewswire March 29, 2017

Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017

GlobeNewswire March 27, 2017

Summit to Extend Ongoing PhaseOut DMD Clinical Trial of Ezutromid in Patients With DMD

GlobeNewswire March 27, 2017

Summit Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference

GlobeNewswire March 15, 2017

Summit Therapeutics Recognises 10th Annual Rare Disease Day

GlobeNewswire February 28, 2017

Summit Therapeutics to Participate in February Investor Conferences

GlobeNewswire February 2, 2017

Summit Outlines Phase 3 Programme for Novel CDI Antibiotic Ridinilazole Following FDA and EMA Regulatory Meetings

GlobeNewswire February 1, 2017

Summit Therapeutics to Report Financial Results for the Third Quarter Ended 31 October 2016 on 15 December 2016

GlobeNewswire December 13, 2016

Summit Enrols Patients in the United States Into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients With DMD

GlobeNewswire November 16, 2016

12 Biggest Mid-Day Losers For Thursday

Benzinga.com  October 6, 2016

Summit Therapeutics Presents Preclinical DMD Data at the 21st International Congress of the World Muscle Society

GlobeNewswire October 6, 2016

Mid-Afternoon Market Update: Dow Drops More Than 100 Points; Summit Therapeutics Shares Spike Higher

Benzinga.com  October 4, 2016

Mid-Day Market Update: Dow Turns Negative; SeaDrill Shares Climb On News Of Potential Refinancing

Benzinga.com  October 4, 2016

Mid-Morning Market Update: Markets Open Higher; Darden Profit Beats Estimates

Benzinga.com  October 4, 2016

15 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  October 4, 2016

Summit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement With Sarepta Therapeutics for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire October 4, 2016

Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire October 4, 2016

Summit Receives Rare Pediatric Disease Designation From US FDA for Ezutromid in Treatment of Duchenne Muscular Dystrophy

GlobeNewswire September 27, 2016